Ultragenyx Pharmaceutical Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Ultragenyx Pharmaceutical Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Novato
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RARE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001515673
- EIN
- 27-2546083
Board of directors
-
Amrit Ray · DirectorSince 2023
-
Corazon (Corsee) D. Sanders · DirectorSince 2023
-
Daniel G. Welch · DirectorSince 2023
-
Deborah Dunsire · DirectorSince 2023
-
Emil D. Kakkis · Director · President & CEOSince 2023
-
Matthew K. Fust · DirectorSince 2023
-
Michael Narachi · DirectorSince 2023
-
Shehnaaz Suliman · DirectorSince 2023
Chief executives
Emil D. Kakkis
· President & CEO
Dates unknown
Director election results
Annual meeting of May 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
89.4%
-
90.1%
-
98.6%
Board connections
6 of this board's directors also sit on 12 other boards.
- via Shehnaaz Suliman
- via Matthew K. Fust
- via Corazon (Corsee) D. Sanders
- via Corazon (Corsee) D. Sanders
- via Matthew K. Fust
- via Amrit Ray
- via Corazon (Corsee) D. Sanders
- via Deborah Dunsire
- via Matthew K. Fust
- via Daniel G. Welch
- via Daniel G. Welch
- via Daniel G. Welch
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $3,952,204
- 28 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Huizenga Theodore Alan Officer (SVP, Chief Accounting Officer) | Open-market sale | −1,283 | $13.57 | $17,410 |
| Sep 3, 2026 | Huizenga Theodore Alan Officer (SVP, Chief Accounting Officer) | Open-market sale | −161 | $13.99 | $2,252 |
| Aug 3, 2026 | Horn Howard Officer (Chief Financial Officer) | Open-market sale | −4,696 | $24.92 | $117,024 |
| Aug 3, 2026 | Karah Herdman Parschauer Officer (EVP and Chief Legal Officer) | Open-market sale | −1,900 | $24.92 | $47,348 |
| Jul 1, 2026 | Horn Howard Officer (Chief Financial Officer) | Open-market sale | −4,698 | $33.13 | $155,645 |
| Jun 15, 2026 | Corazon (Corsee) D. Sanders Director | Open-market sale | −2,000 | $25.05 | $50,100 |
| Jun 15, 2026 | Karah Herdman Parschauer Officer (EVP and Chief Legal Officer) | Open-market sale | −1,899 | $24.62 | $46,753 |
| Jun 1, 2026 | Horn Howard Officer (Chief Financial Officer) | Open-market sale | −4,653 | $23.77 | $110,602 |
| May 18, 2026 | Shehnaaz Suliman Director | Open-market sale | −5,740 | $25.12 | $144,189 |
| May 14, 2026 | Matthew K. Fust Director | Grant or award | +7,751 | — | — |
| May 14, 2026 | Shehnaaz Suliman Director | Grant or award | +7,751 | — | — |
| May 14, 2026 | Amrit Ray Director | Grant or award | +7,751 | — | — |
| May 14, 2026 | Corazon (Corsee) D. Sanders Director | Grant or award | +7,751 | — | — |
| May 14, 2026 | Michael Narachi Director | Grant or award | +7,751 | — | — |
| May 14, 2026 | Daniel G. Welch Director | Grant or award | +7,751 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.